H.C. Wainwright raised the firm’s price target on Maze Therapeutics (MAZE) to $50 from $34 and keeps a Buy rating on the shares. The company’s Phase 1 HV data from the MZE782 showed a robust pharmacodynamics signal, far exceeding JNT-517’s benchmark, the analyst tells investors in a research note. The firm sees “best-in-class potential” for MZE782 in phenylketonuria.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MAZE:
- Maze Therapeutics Advances Clinical Programs Amid Financial Stability
- Maze Therapeutics price target raised to $37 from $30 at BTIG
- Maze Therapeutics price target raised to $34 from $28 at Leerink
- Kroger reports mixed Q2, U.S. CPI rises 0.4% in August: Morning Buzz
- Maze Therapeutics Secures $150M in Private Placement